Neptazane®
Methazolamide · oral tablet
Antiglaucoma
Approved uses
Chronic open-angle glaucoma
50 mg to 100 mg PO two or three times daily
IOP starts falling in 2 to 4 hours, peaks at 6 to 8 hours, and the effect lasts 10 to 18 hours.
Secondary glaucoma, and preoperative acute angle-closure glaucoma
50 mg to 100 mg PO two or three times daily, alone or with miotic and osmotic agents
OFF-LABELNot in the FDA label for this product
Chronic cystoid macular edema in retinitis pigmentosa
50 mg PO BID, the dosage the angiographic responders continued on beyond the 3-week crossover
Masked crossover · n=17
Prospective, double-masked, placebo-controlled crossover trial, N=17, 3 weeks per arm: angiographic macular edema improved in 9 of 17 subjects and visual acuity improved statistically for the group, but a 2 to 4 line gain in at least one eye over placebo occurred in only 3 subjects undilated (4 dilated), and subjective improvement in only 1. Three responders continued at 50 mg BID for a further 6 to 12 weeks and all showed at least partial angiographic rebound. A systematic review of 23 studies concluded oral acetazolamide has the strongest clinical basis and should be first line, with topical dorzolamide the alternative for patients intolerant of it.
Contraindications
- Depressed serum sodium and/or potassium.
- Marked kidney or liver disease or dysfunction.
- Adrenal gland failure.
- Hyperchloremic acidosis.
- Cirrhosis, where use may precipitate hepatic encephalopathy.
- Long-term administration in angle-closure glaucoma, since organic closure of the angle may occur in spite of lowered IOP.
25 mg and 50 mg tablets, in bottles of 90, 500, and 1000
Potent carbonic anhydrase inhibitor; enzyme inhibition decreases secretion of aqueous humor and lowers IOP. The decrease in IOP generally begins within 2 to 4 hours, peaks in 6 to 8 hours, and lasts 10 to 18 hours in total. The mean steady-state plasma half-life is approximately 14 hours, and steady state is reached in 7 days of repeated BID to TID dosing.
Warnings & Precautions
- Sulfonamide hypersensitivity: Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration. If hypersensitivity or other serious reactions occur, discontinue the drug.
- Sulfonamide derivative reactions: Precaution is advised for early detection of reactions common to all sulfonamide derivatives; if they occur, discontinue the drug and institute appropriate therapy.
- Hematologic reactions: Obtain a baseline CBC and platelet count before starting methazolamide and at regular intervals during therapy; if significant changes occur, early discontinuance and institution of appropriate therapy are important.
- Laboratory tests: Periodic monitoring of serum electrolytes is recommended.
- Anorexia, tachypnea, lethargy, coma, and death: These have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors; caution is advised when high-dose aspirin and methazolamide are given together.
- Hypokalemia: Use with caution in patients on steroid therapy because of the potential for developing hypokalemia.
- Hepatic coma: Potassium excretion is increased initially, and in patients with cirrhosis or hepatic insufficiency this could precipitate a hepatic coma.
- Acidosis: In patients with pulmonary obstruction or emphysema, where alveolar ventilation may be impaired, use with caution because methazolamide may precipitate or aggravate acidosis.
- Asian ancestry SJS/TEN risk: Methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) is associated with the HLA-B59 serotype in Korean and Japanese populations. In a study of eight Han Chinese patients with methazolamide-induced SJS/TEN, HLA-B*59:01 was present in 7/8 case patients versus 0/30 methazolamide-tolerant patients.
Common Side Effects
Adverse reactions, occurring most often early in therapy, include paresthesias, particularly tingling in the extremities; hearing dysfunction or tinnitus; fatigue; malaise; loss of appetite; taste alteration; nausea, vomiting, and diarrhea; polyuria; and occasional drowsiness and confusion. Metabolic acidosis and electrolyte imbalance may occur. Transient myopia has been reported and invariably subsides on dose reduction or discontinuance. Other occasional reactions include urticaria, melena, hematuria, glycosuria, hepatic insufficiency, flaccid paralysis, photosensitivity, convulsions, and, rarely, crystalluria and renal calculi. Sulfonamide reactions such as anaphylaxis, fever, rash, and bone marrow depression may occur, and fatalities have occurred, although rarely, from severe sulfonamide reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Pregnancy: Teratogenic (skeletal anomalies) in rats at approximately 40 times the human dose; no adequate and well controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Excretion in human milk is unknown; because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or the drug, weighing its importance to the mother.
Safety and effectiveness in children have not been established.